05.23.13
Quay Pharma has completed the transfer tablet production of one of Actavis’ top-selling drugs to a higher throughput tabletting machine using a MedelPharm compaction simulator.
To help avoid the problems that arise during transfer of tablet production between machines and ensure a smooth transfer between equipment, Quay used an advanced MedelPharm compaction simulator that, according to the company, can mimic any existing tablet press available on the market. The tablets can be compressed at low and high speed, and enables parameters such as compression force and speed to be recorded, as well as ejection force.
For this study tablets were compressed using the current machine profile and the new machine profile. From the data obtained, Quay was able to assess the properties of the Actavis tablet and suggest how a revision in tooling would enable the tablet to be formed effectively on the new equipment, while maintaining the required throughput speeds.
“Quay’s knowledge and experience was invaluable in helping us to successfully transfer production and avoid the disruption that can occur during this process,” said Steve Brown of Actavis.
To help avoid the problems that arise during transfer of tablet production between machines and ensure a smooth transfer between equipment, Quay used an advanced MedelPharm compaction simulator that, according to the company, can mimic any existing tablet press available on the market. The tablets can be compressed at low and high speed, and enables parameters such as compression force and speed to be recorded, as well as ejection force.
For this study tablets were compressed using the current machine profile and the new machine profile. From the data obtained, Quay was able to assess the properties of the Actavis tablet and suggest how a revision in tooling would enable the tablet to be formed effectively on the new equipment, while maintaining the required throughput speeds.
“Quay’s knowledge and experience was invaluable in helping us to successfully transfer production and avoid the disruption that can occur during this process,” said Steve Brown of Actavis.